Preferred Label : macitentan;

MeSH note : structure in first source;

CISMeF synonym : ACT 064992; Actelion-1;

MeSH synonym : N-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-N'-propylaminosulfonamide;

MeSH hyponym : ACT064992; ACT-064992;

Is substance : O;

UNII : Z9K9Y9WMVL;

InChIKey : JGCMEBMXRHSZKX-UHFFFAOYSA-N;

Details


Main resources

You can consult :


http://www.has-sante.fr/portail/jcms/c_2583127/fr/opsumit
http://www.has-sante.fr/portail/jcms/c_2583127/fr/opsumit-macitentan-antagonistes-des-recepteurs-de-l-endotheline
2015
false
false
false
France
French
evaluation of the transparency committee
macitentan
hypertension, pulmonary
adult
administration, oral
macitentan
treatment outcome
drug therapy, combination
idiopathic pulmonary arterial hypertension
Pulmonary arterial hypertension associated with connective tissue disease
Pulmonary arterial hypertension associated with congenital heart disease
orphan drug production
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Familial Primary Pulmonary Hypertension
guidelines for drug use
Product containing macitentan in oral dose form (medicinal product form)
pyrimidines
sulfonamides

---
https://www.ema.europa.eu/medicines/human/EPAR/Opsumit
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
macitentan
macitentan
macitentan
orphan drug production
hypertension, pulmonary
adult
administration, oral
product surveillance, postmarketing
continuity of patient care
drug monitoring
aged
drug interactions
pregnancy
breast feeding
fertility
contraception
reproduction
clinical trials, phase iii as topic
drug evaluation, preclinical
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Product containing macitentan in oral dose form (medicinal product form)
pyrimidines
sulfonamides
pyrimidines
sulfonamides

---
http://www.has-sante.fr/portail/jcms/c_1769783/fr/opsumit
2014
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
macitentan
macitentan
hypertension, pulmonary
adult
administration, oral
macitentan
treatment outcome
drug therapy, combination
idiopathic pulmonary arterial hypertension
Pulmonary arterial hypertension associated with connective tissue disease
Pulmonary arterial hypertension associated with congenital heart disease
orphan drug production
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Familial Primary Pulmonary Hypertension
Product containing macitentan in oral dose form (medicinal product form)
pyrimidines
sulfonamides
pyrimidines
sulfonamides

---
Summary Basis of Decision (SBD) for Opsumit
Macitentan, 10 mg, tablet, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00237
2013
false
Canada
French
English
macitentan
macitentan
drug approval
canada
administration, oral
tablets
hypertension, pulmonary
drug therapy, combination
treatment outcome
rare diseases
clinical trials as topic
pyrimidines
pyrimidines
sulfonamides
sulfonamides
macitentan
Endothelin A Receptor Antagonists
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Endothelin B Receptor Antagonists
drug information
Product containing macitentan in oral dose form (medicinal product form)

---
Nous contacter.
11/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.